Table 1 Characteristics of the patients at baseline (V0)
Characteristics | Cohort (n = 29) | MET-specific alterations | Pan-alterations | ||||
|---|---|---|---|---|---|---|---|
ctDNA Negative | ctDNA Positive | P value | ctDNA Negative | ctDNA Positive | P-value | ||
(n = 15) | (n = 14) | (n = 7) | (n = 22) | ||||
Age - yr, median (range) | 72(47–83) | 72.5(47–83) | 70(54–76) | 0.372 | 72(57–75) | 71.5(47–83) | 0.661 |
Sex, n (%) | 0.272 | 0.682 | |||||
Male | 14(48.3) | 9(60.0) | 5(35.7) | 4(57.1) | 10(45.5) | ||
Female | 15(51.7) | 6(40.0) | 9(64.3) | 3(42.9) | 12(54.5) | ||
Tumor Histology, n (%) | 0.598 | 0.558 | |||||
Adenocarcinoma | 26(89.7) | 14(93.3) | 12(85.7) | 7(100.0) | 19(86.4) | ||
Squamous Cell Carcinoma | 2(6.9) | 1(6.7) | 1(7.1) | 0 | 2(9.1) | ||
Not Otherwise Specified | 1(3.4) | 0 | 1(7.1) | 0 | 1(4.5) | ||
Smoking Status, n (%) | 0.459 | 1 | |||||
Current & Former Smoker | 11(37.9) | 7(46.7) | 4(28.6) | 3(42.9) | 8(36.4) | ||
Non-Smoker | 18(62.1) | 8(53.3) | 10(71.4) | 4(57.1) | 14(63.6) | ||
ECOG Performance Status, n (%) | 0.39 | 1 | |||||
1 | 23(79.3) | 13(86.7) | 10(71.4) | 6(85.7) | 17(77.3) | ||
≥2 | 6(20.9) | 2(13.3) | 4(28.6) | 1(14.4) | 5(22.7) | ||
Disease Stage at Baseline, n (%) | 1 | 0.289 | |||||
Stage III | 6(20.7) | 3(20.0) | 3(21.4) | 0 | 6(27.3) | ||
Stage IV | 23(79.3) | 12(80.0) | 11(75.6) | 7(100.0) | 16(72.7) | ||
Extra-thoracic Metastasis at Baseline, N (%) | 12(41.4) | 6(40.0) | 6(42.9) | 1 | 3(42.9) | 9(40.9) | 1 |
Brain | 4(13.8) | 2(13.3) | 2(14.3) | 0.540 | 1(14.3) | 3(13.6) | 1 |
Bone | 9(31.0) | 6(40) | 3(21.4) | 3(42.9) | 6(27.3) | ||
Adrenal gland | 3(10.3) | 2(13.3) | 1(7.1) | 1(14.3) | 2(9.1) | ||
Liver | 2(6.9) | 0 | 2(14.3) | 0 | 2(9.1) | ||
Intrathoracic Metastasis at Baseline, N (%) | 11(37.9) | 5(45.5) | 6(54.5) | 0.729 | 3(42.9) | 8(36.4) | 0.678 |
Diameter of Target Lesion, mm, median (IQR) | 45(35.6–62.8) | 40.3(28.9–64.0) | 45.5 (41.8-57.1) | 0.631 | 33.3(19.0–71.0) | 46.5(40.7-62.6) | 0.176 |
